Faran
- Company typePrivate
- Founded1950
- HeadquartersKifisiá, Greece
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Faran firmographics
Firmographics- Name
- Faran
- Legal name
- FARAN S.A.
- Website
- https://faran.gr
- Company type
- Private
- Founded year
- 1950
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Faran industry classification
Industry- Product category
- Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)
Keywords
Where Faran is headquartered
LocationHeadquarters
- HQ city
- Kifisiá
- HQ country
- Greece
- HQ region
- Europe
Offices2 records
Markets served
Faran business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Infrastructure, Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Pharmaceutical Product Sales: Faran generates revenue through the sale of branded generics, original, biosimilar, and generic pharmaceutical products across Greece. The company has a portfolio covering Oncology, Haematology, Nephrology, Rheumatology, Endocrinology, Virology, Gynaecology, Pulmonology, Cardiology, and Andrology. The company has achieved consistent sales growth, with 40% growth in 2020, over 20% in 2021, and 30% in 2022, outperforming the broader Greek pharmaceutical market during a period of stagnant public pharmaceutical spending.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Faran product offering
Product offeringCore offering
Faran S.A. is a Greek pharmaceutical company that develops, produces, and distributes branded generics, original, biosimilar, and generic pharmaceutical products across ten therapeutic areas: Oncology, Haematology, Nephrology, Rheumatology, Endocrinology, Andrology, Virology, Gynaecology, Pulmonology, and Cardiology. The company operates GMP-certified manufacturing and distribution facilities in Greece and combines in-house products with exclusive distribution rights for products from international pharmaceutical partners including Novartis, Sandoz, STADA, IBSA, BESIN, Meiji, and Quantum Genomics.
Product overview
FARAN is a Greek pharmaceutical company with 70 years of history offering a portfolio of branded generics, original products, and biosimilars. The therapeutic portfolio covers Oncology, Haematology, Nephrology, Rheumatology, Endocrinology, Pathology, Gynaecology, Virology, Cardiology, and Immunology. The company operates through a combination of in-house branded generics and exclusive distribution partnerships with international pharmaceutical companies including Novartis (Tyverb, Zykadia), Sandoz (Epoetin Alfa), STADA (Movymia biosimilar), Meiji (Spectracef), IBSA, Besins, Quantum Genomics (Firibastat), and others. Currently developing an innovative Nintedanib oral solution through EU-funded industrial research. Products are available to healthcare professionals through registration on the company website.
Differentiator
Problem solved
Functional benefit
Products and services
- Firibastat Innovative pharmaceutical product (BAPAI — Brain Aminopeptidase A Inhibitor) in Phase 3 clinical studies for the treatment of resistant hypertension and heart failure. Developed in partnership with Quantum Genomics and distributed in Greece by Faran.
- Tyverb (Lapatinib) Pharmaceutical product indicated for the treatment of metastatic breast cancer that overexpresses HER2. Distributed in Greece through partnership with Novartis (Hellas) S.A.
- Zykadia (Ceritinib) Pharmaceutical product indicated for the treatment of non-small cell lung cancer presenting ALK rearrangement. Distributed in Greece through partnership with Novartis (Hellas) S.A.
- Movymia (Teriparatide biosimilar) Biosimilar Teriparatide product for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures. Distributed in Greece through partnership with STADA Arzneimittel AG.
- Spectracef (Ceftidoren Pivoxil) 3rd generation oral cephalosporin antibiotic for the treatment of community-acquired respiratory infections and simple soft tissue infections. Distributed in Greece through partnership with Meiji.
- Epoetin Alfa Biotech product for the treatment of anemia-related conditions. Distributed in Greece through an expanded partnership with Sandoz (a Novartis Group company).
- Nintedanib Oral Solution Novel oral solution formulation of Nintedanib (a triple angiokinase inhibitor targeting VEGFR, PDGFR, and FGFR) being developed by Faran for idiopathic pulmonary fibrosis (IPF) and certain types of non-small cell lung cancer, combining indications of Ofev and Vargatef in a single pharmaceutical form.
Quantifiable outcome
- 90.8% EBITDA growth rate (2018-2021), ranked third highest among FortuneGreece's 30 fastest-growing companies in 2022
- +2 more outcomes
Companies that use Faran
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Faran technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Faran partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and secondary.
- Quantum GenomicscoreFaran entered an exclusive partnership with Quantum Genomics on June 30, 2021, for the development and distribution of Firibastat — an innovative pharmaceutical product targeting resistant hypertension and heart failure. Firibastat is a Brain Aminopeptidase A Inhibitor (BAPAI) that represents a truly innovative therapeutic platform. The product was in Phase 3 clinical studies with encouraging early results. Faran holds exclusive licensing and distribution rights for the Greek market. This is the first in a series of planned cardiology collaborations for Faran.
- STADA Arzneimittel AGcoreFaran partnered with STADA Arzneimittel AG to promote and distribute Movymia (Teriparatide biosimilar) in the Greek market for the treatment of osteoporosis in postmenopausal women and men at increased fracture risk. This collaboration strengthens Faran's leadership position in the field of Biotechnology among Greek pharmaceutical companies, as STADA is a global leader in biosimilar research, development, and manufacturing.
- Sandoz (Novartis Group)coreFaran expanded its partnership with Sandoz (a member of the Novartis Group) to promote and distribute a product containing Epoetin Alfa in the Greek market. Following successful prior collaboration, this expanded partnership further strengthens Faran's leadership position in the field of biotechnology, as Sandoz is a global leader in biosimilar research, development, and manufacturing.
- Novartis (Hellas) S.A.coreFaran entered a collaboration with Novartis (Hellas) S.A. for the promotion and distribution of Tyverb (Lapatinib) for metastatic breast cancer HER2-positive patients, and Zykadia (Ceritinib) for ALK-positive non-small cell lung cancer treatment in the Greek market. This collaboration strengthens Faran's leading position in the field of therapeutic oncology among Greek pharmaceutical companies.
- MeijisecondaryFaran partnered with the Japanese pharmaceutical company Meiji for the distribution of Spectracef (Ceftidoren Pivoxil), a 3rd generation oral cephalosporin antibiotic for the treatment of community-acquired respiratory tract infections and simple soft tissue infections in the Greek market. Meiji is a major Japanese pharmaceutical company focused on infectious disease treatments.
- IBSA (Swiss)coreIn 2022, Faran signed agreements with IBSA (Switzerland) and BESIN (France) — major companies in the field of gynaecology and assisted reproduction. Faran covers both the stimulation stage (with gonadotropins) and the luteal phase support stage (with progesterone) for women facing conception difficulties, making it a key player in the assisted reproduction market in Greece.
- BESIN (France)coreIn 2022, Faran signed agreements with IBSA (Switzerland) and BESIN (France) — major companies in the field of gynaecology and assisted reproduction. Faran covers both the stimulation stage (with gonadotropins) and the luteal phase support stage (with progesterone) for women facing conception difficulties, making it a key player in the assisted reproduction market in Greece.
- AtnhassecondaryFaran partnered with the pharmaceutical company Atnhas for the distribution of Bonviva (Ibandronic Acid) in the field of osteoporosis. Bonviva is used to treat osteoporosis in postmenopausal women at risk of fractures. Ibandronic acid is a high-potency bisphosphonate belonging to the nitrogen-containing bisphosphonate group, which selectively acts on bone tissue by specifically inhibiting osteoclast activity.
Scale indicators6 records
Recent moves8 records
Expansion highlights7 records
Faran competitors and assessment
Company assessmentDirect peers
- Help Pharmaceuticals: Greek pharma manufacturer focused on branded generics and specialty therapeutics, serving Greek healthcare professionals through a comparable sales-led model. Closely comparable domestic specialty pharma peer.
- Pharmathen: Greek-headquartered pharmaceutical company developing and supplying generics and specialty products, with a much larger international generics footprint. Comparable in therapeutic breadth and Greek origin, but materially larger scale.
- Specifar Pharmaceuticals: Greek generics and specialty pharmaceutical manufacturer, now part of the broader Teva ecosystem. Highly comparable in branded-generics distribution and Greek-market presence.
- Galenica: Greek pharma company with branded generics, OTC, and consumer health offerings. Direct Greek-market peer with similar sales-led healthcare-professional engagement model.
- DEMO Pharmaceuticals: Greek generics and specialty pharma manufacturer; co-investor with Faran in the Tripoli industrial park and overlapping therapeutic areas including injectables. Same domestic-market positioning and Greek-pharma regulatory context.
- ELPEN Pharmaceuticals: Greek pharmaceutical company with a similarly broad specialty portfolio (cardiology, oncology, respiratory, antibiotics) and co-investor in Faran's Tripoli facility through its Win Medica subsidiary. Closest direct structural peer in Greece.
- Rafarm: Greek pharmaceutical company operating in branded generics, specialty pharma, and injectables with manufacturing in Greece. Overlapping therapeutic categories and Greek-market sales-led go-to-market.
- STADA Arzneimittel: European-focused generics and specialty pharma group with a leading biosimilar portfolio; Faran is STADA's Greek distributor for Movymia. Comparable biosimilar/specialty distribution model and partner-style go-to-market.
Broad incumbents
- Angelini Pharma: Italian-headquartered mid-large specialty pharma group; historically acquired FARAN's commercial operations. Comparable specialty-pharma footprint across Southern Europe and similar branded-generics + specialty distribution model.
Emerging players
- IBSA (Institut Biochimique SA): Swiss specialty pharma with leadership in reproductive medicine, endocrinology, and gynaecology — the exact therapeutic categories where Faran is its Greek partner. Closely comparable in endocrinology/IVF positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Faran social profiles
Digital presenceFaran compliance and trust
Trust signalCompliance5 records
Faran financial estimates
Financial estimateRevenue estimate
Valuation estimate
Faran leadership team
Management profileNumber of profiles
Profiles2 records
Faran funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Faran M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Faran
What does Faran do?
Faran S.A. is a Greek pharmaceutical company that develops, produces, and distributes branded generics, original, biosimilar, and generic pharmaceutical products across ten therapeutic areas: Oncology, Haematology, Nephrology, Rheumatology, Endocrinology, Andrology, Virology, Gynaecology, Pulmonology, and Cardiology. The company operates GMP-certified manufacturing and distribution facilities in Greece and combines in-house products with exclusive distribution rights for products from international pharmaceutical partners including Novartis, Sandoz, STADA, IBSA, BESIN, Meiji, and Quantum Genomics.
Is Faran a public or private company?
Faran is a private company. It is classified as family owned and is currently operating.
When was Faran founded?
Faran was founded in 1950. It employs 51 to 100 people.
Where is Faran based?
Faran is headquartered in Kifisiá, Greece, in the Europe region.
How does Faran make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Faran's main competitors?
Direct peers on record are Help Pharmaceuticals, Pharmathen, Specifar Pharmaceuticals, Galenica, DEMO Pharmaceuticals, ELPEN Pharmaceuticals, Rafarm and STADA Arzneimittel. Angelini Pharma is listed as a broad incumbent. IBSA (Institut Biochimique SA) is listed as an emerging player.
Does Faran have an API?
No public API is recorded for Faran.
What industry is Faran in?
Faran's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.